Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland 20852, USA.
Br J Cancer. 2010 Jun 29;103(1):132-5. doi: 10.1038/sj.bjc.6605722. Epub 2010 Jun 1.
Insulin-like growth factor-I (IGF-I) has been shown to increase kidney growth, glomerular filtration rate, and renal function.
In the prospective Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) study of 29 133 Finnish male smokers aged 50-69 years, serum concentrations of IGF were measured in samples collected in 1985-1988. A total of 100 men with kidney cancer diagnosed > or =5 years after blood collection through 1997 were compared with a subcohort of 400 men; logistic regression models were used to estimate the risk of developing kidney cancer.
Men with IGF-I levels >113 ng ml(-1) were 59% less likely to develop kidney cancer than men with levels < or =113 ng ml(-1) (odds ratio=0.41; 95% confidence interval=0.23-0.75). The IGF binding protein-3 (IGFBP-3) levels did not alter the association. No association was observed between IGFBP-3, or molar ratio of IGF-I/IGFBP-3, and kidney cancer.
Low serum IGF-I levels in this cohort of older middle-aged male smokers are associated with increased kidney cancer risk, independent of IGFBP-3.
胰岛素样生长因子-I（IGF-I）已被证明可增加肾脏生长、肾小球滤过率和肾功能。
在 29133 名年龄在 50-69 岁的芬兰男性吸烟者的前瞻性α-生育酚、β-胡萝卜素癌症预防（ATBC）研究中，于 1985-1988 年采集的样本中测量了 IGF 的血清浓度。通过 1997 年总共比较了 100 名在采血后≥5 年被诊断患有肾癌的男性和 400 名亚组男性；使用逻辑回归模型来估计发生肾癌的风险。
IGF-I 水平>113ng/ml 的男性比 IGF-I 水平≤113ng/ml 的男性发生肾癌的风险低 59%（比值比=0.41；95%置信区间=0.23-0.75）。IGF 结合蛋白-3（IGFBP-3）水平并未改变这种关联。IGFBP-3 或 IGF-I/IGFBP-3 的摩尔比与肾癌之间没有关联。
在这个年龄较大的中年男性吸烟者队列中，低血清 IGF-I 水平与肾癌风险增加相关，与 IGFBP-3 无关。
